Back to top
more

Exelixis (EXEL)

(Delayed Data from NSDQ)

$26.97 USD

26.97
2,911,983

-0.20 (-0.74%)

Updated Aug 9, 2024 04:00 PM ET

After-Market: $26.97 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Novo Nordisk Confirms Bid for Ablynx But Faces Rejection

Novo Nordisk (NVO) confirmed its revised offer made on Dec 22, to acquire Ablynx NV for $3.1 billion.

    Agenus Inc., (AGEN) Jumps: Stock Rises 11.4%

    Agenus Inc. (AGEN) was a big mover last session, as the company saw its shares more than 11% on the day amid huge volumes.

      Alnylam, Sanofi Announce Restructuring Deal for RNAi Products

      Alnylam (ALNY) and Sanofi entered into a strategic restructuring of their RNAi therapeutics rare genetic diseases alliance.

        The Zacks Analyst Blog Highlights: XOMA, Exelixis, Emergent BioSolutions and Medicines

        The Zacks Analyst Blog Highlights: XOMA, Exelixis, Emergent BioSolutions and Medicines

          Exelixis Amends Cabozantinib-Tecentriq Phase Ib Trial

          Exelixis, Inc. (EXEL) announced an amendment to the protocol for the phase Ib trial of cabozantinib combined with Tecentriq whereby there will be four new expansion cohorts to the trial.

            Cancer Space Update: New Regulatory Status for 3 Major Drugs

            Merck's Keytruda receives approval in Japan for bladder cancer. Seattle Genetics' Adcetris and Novartis' Kisqali get regulatory status updates from the FDA.

              Emergent Starts Phase II Study on Anti-influenza Candidate

              Emergent (EBS) initiates a phase II dose-ranging trial to evaluate the safety, pharmacokinetics and clinical benefit of its investigational FLU-IGIV to treat influenza virus infection.

                United Therapeutics (UTHR) Collaborates With Corsair Pharma

                United Therapeutics (UTHR) entered into an exclusive license agreement with Corsair Pharma.

                  Pfizer (PFE) Collaborates With Sangamo for Gene Therapy

                  Pfizer entered into collaboration agreements with Sangamo Therapeutics and private biotech, Arvinas.

                    Inovio Amends Chinese Deal for Immunotherapy, Shares Up

                    Inovio (INO) entered into an amended agreement with ApolloBio Corporation and grants ApolloBio the exclusive right to develop and commercialize VGX-3100 within Greater China.

                      Valeant (VRX) to Settle Allergan Litigation for $290 Million

                      Valeant (VRX) and Pershing Square decided to resolve the claims of the long standing Allergan lawsuit for $290 million. Valeant will now pay 33% of the costs, down from the previous agreement of 60%.

                        Will Exelixis (EXEL) be Able to Carry '17 Momentum in 2018?

                        Exelixis (EXEL) had a phenomenal run in 2017 driven by sales of Cabometyx and we expect the momentum to continue in 2018 on the back of the label expansion of the drug.

                          Exelixis' Cabometyx Gets FDA Nod for First-Line Kidney Cancer

                          Exelixis (EXEL) received a significant boost with the approval of label expansion of lead drug Cabometyx for first-line kidney cancer.

                            Endo (ENDP) Earnings & Revenues Beat in Q3, Generics Weak

                            Endo (ENDP) announced better-than-expected results for the third quarter. However, weakness in the generics segment persist and will impact results.

                              Perrigo (PRGO) Q3 Earnings Top, 2017 View Raised, Shares Up

                              Perrigo (PRGO) posts better-than-expected earnings with revenues also beating estimates. The company ups its guidance, courtesy of a continued positive execution across all business segments.

                                Merrimack (MACK) Q3 Loss Narrower than Expected, Stock Up

                                Merrimack (MACK) reported narrower-than-expected loss in the third quarter. With no marketed product after Onivyde sale, the company is now focused on developing its pipeline candidates.

                                  Pacira (PCRX) Posts Earnings in Q3, Revenues Lag Estimates

                                  Pacira's (PCRX) earnings surpassed estimates but sales missed the same in the third quarter of 2017. The company remains focused on the label expansion of Exparel.

                                    Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q3

                                    Catalyst Pharma (CPRX) remains focused on the development of its pipeline candidate firdapse in the third quarter of 2017.

                                      VIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down

                                      VIVUS (VVUS) reported third-quarter results wherein it reported narrower-than- expected loss. However, Qsymia sales fell from the year-ago period.

                                        Aerie (AERI) Q3 Loss Wider Than Expected, Pipeline in Focus

                                        Increased operating expenses mar Aerie's (AERI) Q3 performance.

                                          Jazz Pharmaceuticals (JAZZ) Q3 Earnings Top, 2017 View Cut

                                          Jazz Pharmaceuticals (JAZZ) earnings beat estimates while revenues miss the same in Q3. The company also cuts its guidance due to lower-than-expected sales from Xyrem.

                                            Regeneron (REGN) Beats on Q3 Earnings & Sales, Shares Up

                                            Regeneron reported impressive results in the third quarter driven by strong performance of Eylea.

                                              Agenus (AGEN) Reports In Line Loss in Q3, Revenues Lag

                                              Agenus (AGEN) incurred in line loss but sales missed estimates in the third quarter of 2017.

                                                Infinity (INFI) Q3 Loss Narrower than Expected, View Intact

                                                Infinity Pharmaceuticals (INFI) Q3 loss was narrower than estimates and the year-ago quarter loss.

                                                  AVEO Pharmaceuticals Q3 Loss Narrows, Focus on Fotivda

                                                  AVEO Pharmaceuticals reported narrower-than-expected adjusted loss in the third quarter. Moreover, it received approval for its first drug, Fotivda, which was approved in EU for bladder cancer.